USRE45573E1 - Process for producing imide compound - Google Patents

Process for producing imide compound Download PDF

Info

Publication number
USRE45573E1
USRE45573E1 US14/137,464 US200414137464A USRE45573E US RE45573 E1 USRE45573 E1 US RE45573E1 US 200414137464 A US200414137464 A US 200414137464A US RE45573 E USRE45573 E US RE45573E
Authority
US
United States
Prior art keywords
hydrochloric acid
aqueous hydrochloric
hydrochloride
acid solution
imide compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active, expires
Application number
US14/137,464
Inventor
Yuzo Kakiya
Mayumi Oda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sumitomo Pharma Co Ltd
Original Assignee
Sumitomo Dainippon Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
Priority claimed from JP2003281860 external-priority
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34100970&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=USRE45573(E1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sumitomo Dainippon Pharma Co Ltd filed Critical Sumitomo Dainippon Pharma Co Ltd
Priority to US14/137,464 priority Critical patent/USRE45573E1/en
Assigned to SUMITOMO DAINIPPON PHARMA CO., LTD. reassignment SUMITOMO DAINIPPON PHARMA CO., LTD. CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: DAINIPPON SUMITOMO PHARMA CO., LTD.
Application granted granted Critical
Publication of USRE45573E1 publication Critical patent/USRE45573E1/en
Assigned to Sumitomo Pharma Co., Ltd. reassignment Sumitomo Pharma Co., Ltd. CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: SUMITOMO DAINIPPON PHARMA CO., LTD.
Active legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

The present invention provides an excellent industrial process for producing an imide compound hydrochloride.
The process for producing an imide compound hydrochloride of the formula (2):
Figure USRE045573-20150623-C00001

or an enantiomer thereof,
which comprises treating a compound of the formula (1):
Figure USRE045573-20150623-C00002

or an enantiomer thereof with an aqueous hydrochloric acid solution in a hydrophilic solvent, followed by crystallizing the resultant.

Description

This application is a reissue application of U.S. Pat. No. 7,605,260, issued on Oct. 20, 2009, from U.S. patent application Ser. No. 10/565,105, which is the National Stage Entry of International Application No. PCT/JP2004/011035, filed Jul. 27, 2004, which claims the benefit of priority of Japan Application No. 2003-281860, filed on Jul. 29, 2003, all of which are incorporated herein by reference in their entirety.
TECHNICAL FIELD
The present invention relates to a process for producing an imide compound of the formula (2) or an enantiomer thereof, which is useful as a psychotropic substance.
Figure USRE045573-20150623-C00003
BACKGROUND ART
It has been reported that the imide compound hydrochloride of the above formula (2) can be produced by treating an imide compound in free form of the formula (1):
Figure USRE045573-20150623-C00004

with a hydrogen chloride 2-propanol solution in acetone, and crystallizing the resultant. However, said process is not sufficient enough for an industrial process from the aspect of the availability and the handling of the reagents to be used therein (cf., JP-A-5-17440).
DISCLOSURE OF INVENTION
An object of the present invention is to provide an excellent industrial process for producing the above imide compound hydrochloride.
The present inventors have intensively studied in order to solve the above-mentioned problems, and found that the imide compound hydrochloride of the above formula (2) can be obtained in high quality and high yield under moderate and simple reaction conditions by treating the compound of the above formula (1) with an aqueous hydrochloric acid solution in a hydrophilic solvent, and crystallizing the resultant, and they have accomplished the present invention.
Namely, the present invention relates to the following:
[1] A process for producing an imide compound hydrochloride of the formula (2):
Figure USRE045573-20150623-C00005

or an enantiomer thereof,
which comprises treating a compound of the formula (1):
Figure USRE045573-20150623-C00006

or an enantiomer thereof with an aqueous hydrochloric acid solution in a hydrophilic solvent, and crystallizing the resultant.
[2] The process for producing the imide compound hydrochloride according to the above [1], wherein the hydrophilic solvent is a ketone solvent.
[3] The process for producing the imide compound hydrochloride according to the above [1], wherein the hydrophilic solvent is acetone.
[4] The process for producing the imide compound hydrochloride according to any one of the above [1], [2] and [3], wherein the aqueous hydrochloric acid solution is a 1.8-14.4% aqueous hydrochloric acid solution.
[5] The process for producing the imide compound hydrochloride according to any one of the above [1], [2] and [3], wherein the aqueous hydrochloric acid solution is a 3.0-5.0% aqueous hydrochloric acid solution.
The imide compound hydrochloride of the above formula (2) or an enantiomer thereof (hereinafter, occasionally simply referred to as the imide compound hydrochloride of the formula (2) or the imide compound hydrochloride (2)) can be produced by treating a solution of the compound of the above formula (1) or an enantiomer thereof (hereinafter, occasionally simply referred to as the compound of the formula (1) or the compound (1)) in a hydrophilic solvent with an aqueous hydrochloric acid solution, and crystallizing the resultant. The compound of the formula (1) can be produced according to the method disclosed in JP-A-5-17440.
The hydrophilic solvent includes, for example, ketone solvents, ether solvents, and alcohol solvents, and preferable ones are ketone solvents.
The ketone solvent includes, for example, dialkyl ketones having not more than 6 carbon atoms such as acetone, methyl ethyl ketone, 4-methyl-2-pentanone, etc. Preferable ones are acetone, methyl ethyl ketone, and most preferable one is acetone.
The ether solvent includes, for example, cyclic ethers having not more than 6 carbon atoms such as tetrahydrofuran, dioxane, etc., and acyclic dialkyl ethers having not more than 6 carbon atoms such as dimethyl ether, diethyl ether, etc. Preferable one is tetrahydrofuran.
The alcohol solvent includes, for example, alcohols having not more than 6 carbon atoms such as 2-propanol, ethanol, methanol, ethylene glycol, etc., and preferable one is 2-propanol.
The hydrophilic solvent is usually used in an amount of 3 to 100 times (by weight) of the amount of the compound (1), preferably in an amount of 5 to 30 times (by weight) of the amount of the compound (1), and more preferably in an amount of 7 to 15 times (by weight) of the amount of the compound (1).
The temperature for dissolving the compound (1) in a hydrophilic solvent is usually in the range of 0° C. to a reflux temperature, preferably in the range of 25° C. to a reflux temperature. For the solvents other than ether solvents, the temperature is more preferably in the range of 45° C. to a reflux temperature.
The concentration of hydrogen chloride in the aqueous hydrochloric acid solution is not necessarily specified. For example, an aqueous hydrochloric acid solution in a concentration of 0.3-36% may be exemplified. The concentration of hydrogen chloride in the aqueous hydrochloric acid solution is preferably a 1.8 to 14.4% aqueous hydrochloric acid solution, more preferably about 3.0 to 5.0% aqueous hydrochloric acid solution, from view point of (i) the amount of the hydrophilic solvent contained in the crystals of the imide compound hydrochloride, (ii) the amount of the impurities contained in the crystals of the imide compound hydrochloride, and (iii) the yield (see Table 1).
The equivalents of the hydrochloric acid to be used is usually in the range of 0.9 to 3 equivalents, preferably in the range of 1.0 to 2.0 equivalents, more preferably in the range of 1.0 to 1.3 equivalent, to one equivalent of the compound (1).
The temperature for treating the compound (1) with an aqueous hydrochloric acid solution in a hydrophilic solvent and crystallizing the resultant is not necessarily specified, and these processes may be carried out either under cooling or warming. The reaction temperature is usually in the range of 0° C. to a reflux temperature, preferably in the range of 25° C. to a reflux temperature, and more preferably in the range of 50° C. to a reflux temperature.
The method for mixing a solution of the compound (1) in a hydrophilic solvent and an aqueous hydrochloric acid solution is not necessarily specified. For example, a method of adding an aqueous hydrochloric acid solution into a solution of the compound (1) in a hydrophilic solvent, a method of adding a solution of the compound (1) in a hydrophilic solvent into an aqueous hydrochloric acid solution, a method of simultaneously adding both a solution of the compound (1) in a hydrophilic solvent and an aqueous hydrochloric acid solution into the reactor vessel, a method of adding a mixture of an aqueous hydrochloric acid solution and a hydrophilic solvent into a solution of the compound (1) in a hydrophilic solvent, a method of adding a solution of the compound (1) in a hydrophilic solvent into a mixture of an aqueous hydrochloric acid solution and a hydrophilic solvent, etc. are exemplified.
The time to be needed for mixing a solution of the compound (1) in a hydrophilic solvent and an aqueous hydrochloric acid solution is not necessarily specified. For example, a method of mixing both solutions at once, a method of mixing by adding one of them into the other with spending an extended period of time, are exemplified. A method of mixing by adding one of them into the other with spending an extended period of time is usually employed. In this case, the time to be needed is, for example, in the range of from one minute to 6 hours, preferably in the range of from 3 minutes to 3 hours.
The crystals of the imide compound hydrochloride precipitated by treatment with hydrochloric acid are separated by a conventional method, for example, by filtration, to give the imide compound hydrochloride of the above formula (2). The temperature of the reaction slurry prior to the filtration is not necessarily specified, and the filtration is usually carried out after the reaction slurry is sufficiently crystallized by cooling or warming. The temperature for keeping the reaction slurry is usually in the range of −20° C. to 60° C., preferably in the range of −10° C. to 25° C., more preferably in the range of 0 to 10° C.
The imide compound hydrochloride (2) thus separated may be obtained in the solvent-free form by drying. The drying method is not necessarily specified, for example, drying under reduced pressure, drying under atmospheric pressure, drying with aeration of inert gas such as nitrogen or air flow. The drying temperature is not necessarily specified, and the drying is carried either under cooling or warming, preferably at a temperature of 0 to 50° C.
The imide compound hydrochloride represented by the above formula (2) has been known to be useful as an agent for treatment of schizophrenia, etc. (cf., JP-A-5-17440).
By using an aqueous hydrochloric acid solution, which is easily obtained and excellent in safety and operability, without a necessity to produce from a hydrochloric acid gas and a solvent by mixing them like hydrochloric acid/solvent system, the industrially advantageous production of the imide compound hydrochloride becomes possible.
The present invention is illustrated in more detail by Examples, but the present invention should not be construed to be limited thereto.
EXAMPLE 1
Figure USRE045573-20150623-C00007
(1R,2S,3R,4S)-N-[(1R,2R)-2-[4-(1,2-Benzisothiazol-3-yl)-1-piperazinylmethyl]-1-cyclohexylmethyl]-2,3-bicyclo[2.2.1]heptanedicarboxyimide (8.25 g) was dissolved in acetone (102 g) with heating under reflux to give an acetone solution thereof. To this solution was added dropwise a 3.6% aqueous hydrochloric acid solution (18.5 g, 1.1 equivalent) over a period of about 15 minutes while the solution was kept at about 55° C. After the addition was completed, the reaction mixture was stirred at about 60° C. for one hour. The reaction mixture was cooled to 0° C., and stirred at the same temperature for one hour. The mixture was filtered, and the resulting solid was dried at room temperature under reduced pressure to give (1R,2S,3R,4S)-N-[(1R,2R)-2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinylmethyl]-1-cyclohexylmethyl]-2,3-bicyclo-[2.2.1]heptanedicarboxyimide hydrochloride (7.5 g, yield: 85%).
EXAMPLE 2
(1R,2S,3R,4S)-N-[(1R,2R)-2-[4-(1,2-Benzisothiazol-3-yl)-1-piperazinylmethyl]-1-cyclohexylmethyl]-2,3-bicyclo[2.2.1]heptanedicarboxyimide (8.25 g) was dissolved in acetone (102 g) with heating under reflux to give an acetone solution thereof. To this acetone solution was added dropwise a 3.6% aqueous hydrochloric acid solution (18.5 g, 1.1 equivalent) at about 55° C. over a period of about 15 minutes. Then, the mixture was stirred at about 60° C. for one hour. The reaction mixture was cooled to 0° C., and stirred at the same temperature for one hour. The mixture was filtered, and the resulting solid was dried at room temperature under reduced pressure to give (1R,2S,3R,4S)-N-[(1R,2R)-2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinylmethyl]-1-cyclohexylmethyl]-2,3-bicyclo[2.2.1]heptanedicarboxyimide hydrochloride (7.5 g, yield: 85%).
EXAMPLE 3
In the procedure in Example 2, a 3.6% aqueous hydrochloric acid solution (1.1 equivalent) was added dropwise over a period of one hour. (1R,2S,3R,4S)-N-[(1R,2R)-2-[4-(1,2-Benzisothiazol-3-yl)-1-piperazinylmethyl]-1-cyclohexylmethyl]-2,3-bicyclo[2.2.1]heptanedicarboxyimide hydrochloride was obtained in the same manner as in Example 2 except for the time for addition.
EXAMPLE 4
(1R,2S,3R,4S)-N-[(1R,2R)-2-[4-(1,2-Benzisothiazol-3-yl)-1-piperazinylmethyl]-1-cyclohexylmethyl]-2,3-bicyclo[2.2.1]heptanedicarboxyimide (3.5 g) was dissolved in acetone (43 g) with heating under reflux to give an acetone solution. To this acetone solution was added dropwise a 1.8% aqueous hydrochloric acid solution (1.1 equivalent) at about 55° C. over a period of about 5 minutes. Then, the mixture was stirred at about 60° C. for one hour. The reaction mixture was cooled to 0° C., and stirred at the same temperature for one hour. The mixture was filtered, and the resulting solid was dried at room temperature under reduced pressure to give (1R,2S,3R,4S)-N-[(1R,2R)-2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinylmethyl]-1-cyclohexylmethyl]-2,3-bicyclo[2.2.1]heptanedicarboxyimide hydrochloride.
EXAMPLE 5
(1R,2S,3R,4S)-N-[(1R,2R)-2-[4-(1,2-Benzisothiazol-3-yl)-1-piperazinylmethyl]-1-cyclohexylmethyl]-2,3-bicyclo[2.2.1]heptanedicarboxyimide hydrochloride was obtained in the same manner as in Example 4 except that a 3.0% aqueous hydrochloric acid solution (1.1 equivalent) was used instead of the 1.8% aqueous hydrochloric acid solution (1.1 equivalent) in Example 4.
EXAMPLE 6
(1R,2S,3R,4S)-N-[(1R,2R)-2-[4-(1,2-Benzisothiazol-3-yl)-1)-1-piperazinylmethyl]-1-cyclohexylmethyl]-2,3-bicyclo[2.2.1]heptanedicarboxyimide hydrochloride was obtained in the same manner as in Example 4 except that a 3.6% aqueous hydrochloric acid solution (1.1 equivalent) was used instead of the 1.8% aqueous hydrochloric acid solution (1.1 equivalent) in Example 4.
EXAMPLE 7
(1R,2S,3R,4S)-N-[(1R,2R)-2-[4-(1,2-Benzisothiazol-3-yl)-1-piperazinylmethyl]-1-cyclohexylmethyl]-2,3-bicyclo[2.2.1]heptanedicarboxyimide hydrochloride was obtained in the same manner as in Example 4 except that a 4.2% aqueous hydrochloric acid solution (1.1 equivalent) was used instead of the 1.8% aqueous hydrochloric acid solution (1.1 equivalent) in Example 4.
EXAMPLE 8
(1R,2S,3R,4S)-N-[(1R,2R)-2-[4-(1,2-Benzisothiazol-3-yl)-1-piperazinylmethyl]-1-cyclohexylmethyl]-2,3-bicyclo[2.2.1]heptanedicarboxyimide hydrochloride was obtained in the same manner as in Example 4 except that a 5.0% aqueous hydrochloric acid solution (1.1 equivalent) was used instead of the 1.8% aqueous hydrochloric acid solution (1.1 equivalent) in Example 4.
EXAMPLE 9
(1R,2S,3R,4S)-N-[(1R,2R)-2-[4-(1,2-Benzisothiazol-3-yl)-1-piperazinylmethyl]-1-cyclohexylmethyl]-2,3-bicyclo[2.2.1]heptanedicarboxyimide hydrochloride was obtained in the same manner as in Example 1 except that a 5.0% aqueous hydrochloric acid solution (1.1 equivalent) was used instead of the 3.6% aqueous hydrochloric acid solution (1.1 equivalent) in Example 1.
EXAMPLE 10
A 5.0% aqueous hydrochloric acid solution (1.1 equivalent) was added dropwise over a period of one hour instead of the 3.6% aqueous hydrochloric acid solution (1.1 equivalent) in Example 2. (1R,2S,3R,4S)-N-[(1R,2R)-2-[4-(1,2-Benzisothiazol-3-yl)-1-piperazinylmethyl]-1-cyclohexylmethyl]-2,3-bicyclo[2.2.1]heptanedicarboxyimide hydrochloride was obtained in the same manner as in Example 2 except for the time for addition and the concentration of the aqueous hydrochloric acid solution.
EXAMPLE 11
(1R,2S,3R,4S)-N-[(1R,2R)-2-[4-(1,2-Benzisothiazol-3-yl)-1-piperazinylmethyl]-1-cyclohexylmethyl]-2,3-bicyclo[2.2.1]heptanedicarboxyimide hydrochloride was obtained in the same manner as in Example 4 except that a 7.2% aqueous hydrochloric acid solution (1.1 equivalent) was used instead of the 1.8% aqueous hydrochloric acid solution (1.1 equivalent) in Example 4.
EXAMPLE 12
(1R,2S,3R,4S)-N-[(1R,2R)-2-[4-(1,2-Benzisothiazol-3-yl)-1-piperazinylmethyl]-1-cyclohexylmethyl]-2,3-bicyclo[2.2.1]heptanedicarboxyimide hydrochloride was obtained in the same manner as in Example 4 except that a 14.4% aqueous hydrochloric acid solution (1.1 equivalent) was used instead of the 1.8% aqueous hydrochloric acid solution (1.1 equivalent) in Example 4.
EXAMPLE 13
(1R,2S,3R,4S)-N-[(1R,2R)-2-[4-(1,2-Benzisothiazol-3-yl)-1-piperazinylmethyl]-1-cyclohexylmethyl]-2,3-bicyclo[2.2.1]heptanedicarboxyimide hydrochloride was obtained in the same manner as in Example 4 except that a 36% aqueous hydrochloric acid solution (1.1 equivalent) was used instead of the 1.8% aqueous hydrochloric acid solution (1.1 equivalent) in Example 4.
EXAMPLE 14
In the procedure of Example 1, a solution of (1R,2S,3R,4S)-N-[(1R,2R)-2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinylmethyl]-1-cyclohexylmethyl]-2,3-bicyclo[2.2.1]heptanedicarboxyimide (8.25 g) in acetone was added dropwise into a 3.6% aqueous hydrochloric acid solution (18.5 g, 1.1 equivalent) over a period of one hour. (1R,2S,3R,4S)-N-[(1R,2R)-2-[4-(1,2-Benzisothiazol-3-yl)-1-piperazinylmethyl]-1-cyclohexylmethyl]-2,3-bicyclo[2.2.1]heptanedicarboxyimide hydrochloride was obtained in the same manner as in Example 1 except for the method of addition.
(1R,2S,3R,4S)-N-[(1R,2R)-2-[4-(1,2-Benzisothiazol-3-yl)-1-piperazinylmethyl]-1-cyclohexylmethyl]-2,3-bicyclo[2.2.1]heptanedicarboxyimide hydrochloride obtained in Examples 1-14 was analyzed, and the results thereof are shown in Table 1.
TABLE 1
Ex. No.
1 2 3 4 5 6 7 8 9 10 11 12 13 14
Conc. of aq. HCl 3.6% 3.6% 3.6% 1.8% 3.0% 3.6% 4.2% 5.0% 5.0% 5.0% 7.2% 14.4%   36% 3.6%
solution (% by weight)
Yield  85%  85%  85%  65%  84%  85%  89%  90%  90%  90%  96%  97%  97%  85%
Acetone in the 0.1% 0.1% 0.1% 0.1% 0.1% 0.1% 0.1% 0.1% 0.1% 0.1% 0.5% 0.5% 1.0% 0.1%
crystals (% by weight)
Amount of impurities 0.1% 0.1% 0.1% 0.1% 0.1% 0.1% 0.1% 0.1% 0.1% 0.1% 0.1% 0.1% 0.2% 0.1%
in the crystals
The amounts of acetone in the crystals were determined by gas chromatography using a capillary column and FID detector, and the amounts of impurities were determined by liquid chromatography using a reversed phase ODS column and a UV detector.
EXAMPLE 15
(1R,2 S,3R,4S)-N-[(1R,2R)-2-[4-(1,2-Benzisothiazol-3-yl)-1-piperazinylmethyl]-1-cyclohexylmethyl]-2,3-bicyclo[2.2.1]heptanedicarboxyimide (1.5 g) was dissolved in tetrahydrofuran (5.5 g) with heating under reflux to give a tetrahydrofuran solution. To this solution was added a 3.6% hydrochloric acid (6.18 g) under reflux, and the reaction mixture was cooled to 20° C., filtered, and the resulting solid was dried under reduced pressure to give (1R,2S,3R,4S)-N-[(1R,2R)-2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinylmethyl]-1-cyclohexylmethyl]-2,3-bicyclo-[2.2.1]heptanedicarboxyimide hydrochloride (1.34 g, yield: 83%).
EXAMPLE 16
(1R,2S,3R,4S)-N-[(1R,2R)-2-[4-(1,2-Benzisothiazol-3-yl)-1-piperazinylmethyl]-1-cyclohexylmethyl]-2,3-bicyclo[2.2.1]heptanedicarboxyimide (2.0 g) was dissolved in methyl ethyl ketone (22 g) with heating at about 60° C. to give a methyl ethyl ketone solution. To this solution was added a 3.6% hydrochloric acid (4.52 g) at about 60° C., and the reaction mixture was cooled to 0° C. The reaction mixture was filtered, and the resulting solid was dried under reduced pressure at room temperature to give (1R,2S,3R,4S)-N-[(1R,2R)-2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinylmethyl]-1-cyclohexylmethyl]-2,3-bicyclo[2.2.1]heptanedicarboxyimide hydrochloride (0.84 g, yield: 39%).
EXAMPLE 17
(1R,2S,3R,4S)-N-[(11R,2R)-2-[4-(1,2-Benzisothiazol-3-yl)-1-piperazinylmethyl]-1-cyclohexylmethyl]-2,3-bicyclo[2.2.1]heptanedicarboxyimide (2.0 g) was dissolved in 2-propanol (200 g) with heating at about 80° C. to give a 2-propanol solution. To this solution was added a 14.4% hydrochloric acid (1.54 g) at about 80° C., and the reaction mixture was cooled to 0° C. The reaction mixture was filtered, and the resulting solid was dried under reduced pressure at room temperature to give (1R,2S,3R,4S)-N-[(1R,2R)-2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinylmethyl]-1-cyclohexylmethyl]-2,3-bicyclo[2.2.1]heptanedicarboxyimide hydrochloride (2.05 g, yield: 95%).
INDUSTRIAL APPLICABILITY
According to the present invention, it becomes possible to provide an industrially advantageous process for producing the imide compound hydrochloride of the above formula (2).

Claims (12)

The invention claimed is:
1. A process for producing an imide compound hydrochloride of the formula (2):
Figure USRE045573-20150623-C00008
or an enantiomer thereof,
which comprises treating a compound of the formula (1):
Figure USRE045573-20150623-C00009
or an enantiomer thereof with 1.8 to 5.0% aqueous hydrochloric acid solution in acetone, crystallizing the resultant hydrochloride of the formula (2), and isolating the crystallized hydrochloride of the formula (2).
2. The process for producing the imide compound hydrochloride according to claim 1, wherein the aqueous hydrochloric acid solution is a 3.0-5.0% aqueous hydrochloric acid solution.
3. The imide compound hydrochloride of the formula (2)
Figure USRE045573-20150623-C00010
which is obtained by the process according to claim 1 or 2.
4. The imide compound hydrochloride as set forth in claim 3, which has a residual acetone content of about 0.1% by weight or less.
5. The imide compound hydrochloride as set forth in claim 3, which has impurities of about 0.1% by weight or less.
6. The imide compound hydrochloride as set forth in claim 3, which has a residual acetone content of about 0.1% by weight or less, and which has impurities of about 0.1% by weight or less.
7. A process for producing an imide compound hydrochloride of the formula (2):
Figure USRE045573-20150623-C00011
which comprises treating a compound of the formula (1):
Figure USRE045573-20150623-C00012
with 1.8 to 5.0% aqueous hydrochloric acid solution in acetone, crystallizing the resultant hydrochloride of the formula (2), and isolating the crystallized hydrochloride of the formula (2).
8. The process for producing the imide compound hydrochloride according to claim 7, wherein the aqueous hydrochloric acid solution is a 3.0-5.0% aqueous hydrochloric acid solution.
9. The imide compound hydrochloride of the formula (2)
Figure USRE045573-20150623-C00013
which is obtained by the process according to claim 7 or 8.
10. The imide compound hydrochloride as set forth in claim 9, which has a residual acetone content of about 0.1% by weight or less.
11. The imide compound hydrochloride as set forth in claim 9, which has impurities of about 0.1% by weight or less.
12. The imide compound hydrochloride as set forth in claim 9, which has a residual acetone content of about 0.1% by weight or less, and which has impurities of about 0.1% by weight or less.
US14/137,464 2003-07-29 2004-07-27 Process for producing imide compound Active 2025-07-18 USRE45573E1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US14/137,464 USRE45573E1 (en) 2003-07-29 2004-07-27 Process for producing imide compound

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2003281860 2003-07-29
JP2003-281860 2003-07-29
PCT/JP2004/011035 WO2005009999A1 (en) 2003-07-29 2004-07-27 Process for producing imide compound
US14/137,464 USRE45573E1 (en) 2003-07-29 2004-07-27 Process for producing imide compound
US10/565,105 US7605260B2 (en) 2003-07-29 2004-07-27 Process for producing imide compound

Publications (1)

Publication Number Publication Date
USRE45573E1 true USRE45573E1 (en) 2015-06-23

Family

ID=34100970

Family Applications (2)

Application Number Title Priority Date Filing Date
US14/137,464 Active 2025-07-18 USRE45573E1 (en) 2003-07-29 2004-07-27 Process for producing imide compound
US10/565,105 Active 2025-07-18 US7605260B2 (en) 2003-07-29 2004-07-27 Process for producing imide compound

Family Applications After (1)

Application Number Title Priority Date Filing Date
US10/565,105 Active 2025-07-18 US7605260B2 (en) 2003-07-29 2004-07-27 Process for producing imide compound

Country Status (12)

Country Link
US (2) USRE45573E1 (en)
EP (1) EP1652848B1 (en)
JP (1) JP4610485B2 (en)
KR (1) KR101085806B1 (en)
CN (1) CN100422178C (en)
AT (1) AT543817T (en)
AU (1) AU2004259305B2 (en)
BR (1) BRPI0413081B8 (en)
CA (1) CA2538265C (en)
DK (1) DK1652848T3 (en)
ES (1) ES2378990T3 (en)
WO (1) WO2005009999A1 (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2390353T3 (en) * 2005-06-13 2012-11-12 Dainippon Sumitomo Pharma Co., Ltd. Dissolution Preparation
MY153868A (en) 2007-04-04 2015-03-30 Merck Sharp & Dohme Therapeutic agents
WO2011093522A1 (en) * 2010-01-28 2011-08-04 Dainippon Sumitomo Pharma Co., Ltd. A cycloalkane derivative
HUE030294T2 (en) 2010-04-26 2017-04-28 Sumitomo Dainippon Pharma Co Ltd A process of a quaternary ammonium salt
CN107625728A (en) 2010-10-18 2018-01-26 大日本住友制药株式会社 Injectable sustained release preparation
WO2012107890A2 (en) * 2011-02-10 2012-08-16 Ranbaxy Laboratories Limited Crystalline forms of lurasidone hydrochloride
WO2012123858A1 (en) * 2011-03-14 2012-09-20 Ranbaxy Laboratories Limited Amorphous lurasidone hydrochloride
US8981095B2 (en) 2011-07-28 2015-03-17 Mapi Pharma Ltd. Intermediate compounds and process for the preparation of lurasidone and salts thereof
CZ304027B6 (en) * 2011-08-18 2013-08-28 Farmak, A. S. Process for preparing (1R,2S,3R,4S)-N-[(1R,2R)-2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinylmethyl]-1-cyclohexylmethyl[2,3-bicyclo[2.2.1]heptanedicarboxamide hydrochloride
CN102952064A (en) * 2011-08-19 2013-03-06 天津药物研究院 Preparation method of medicine intermediate cis-ex-bicyclo[2.2.1]heptane-2.3-dicarboximide
WO2013030722A1 (en) 2011-08-26 2013-03-07 Ranbaxy Laboratories Limited Crystalline lurasidone hydrochloride
CN103130795A (en) * 2011-12-02 2013-06-05 苏州二叶制药有限公司 Lurasidone HCl crystal A and purpose thereof
CN103130794B (en) * 2011-12-02 2016-06-22 苏州二叶制药有限公司 The preparation method of the crystal A of Lurasidone keto hydrochloride
US9409899B2 (en) 2012-02-13 2016-08-09 Cadila Healthcare Limited Process for preparing benzisothiazol-3-yl-piperazin-1-yl-methyl-cyclo hexylmethanisoindol-1,3-dione and its intermediates
CN103360383B (en) * 2012-04-11 2016-07-06 上海医药工业研究院 Crystal form B of Lurasidone HCl and preparation method thereof
CN102746289B (en) * 2012-04-28 2016-06-08 上海医药工业研究院 The preparation method of a kind of lurasidone hydrochloride
WO2013190455A2 (en) * 2012-06-18 2013-12-27 Shasun Pharmaceuticals Limited Process for the preparation of lurasidone hydrochloride
CN102863437A (en) * 2012-09-04 2013-01-09 济南百诺医药科技开发有限公司 Preparation method of lurasidone
WO2014064714A2 (en) * 2012-10-22 2014-05-01 Glenmark Pharmaceuticals Limited; Glenmark Generics Limited Process for preparation of lurasidone hydrochloride
CN102911170A (en) * 2012-11-15 2013-02-06 苏州第壹制药有限公司 Method for preparing imide compound hydrochloride
CN104031041A (en) * 2013-03-06 2014-09-10 江苏恩华药业股份有限公司 New crystal forms of lurasidone hydrochloride and preparation method thereof
CN103539794A (en) * 2013-10-17 2014-01-29 常州大学 Salifying method of lurasidone hydrochloride
CZ306203B6 (en) * 2013-12-06 2016-09-29 Zentiva, K. S Lurasidone synthesis process
PL3154967T3 (en) 2014-06-16 2021-01-11 Johnson Matthey Public Limited Company Processes for making alkylated arylpiperazine and alkylated arylpiperidine compounds including novel intermediates
US10426770B2 (en) 2014-10-14 2019-10-01 Jubilant Generics Limited Process for the preparation of Lurasidone hydrochloride
SG11202008204QA (en) 2018-02-28 2020-09-29 Sumitomo Dainippon Pharma Co Ltd Aqueous suspension pharmaceutical preparation
JPWO2019167978A1 (en) 2018-02-28 2021-02-04 大日本住友製薬株式会社 Aqueous suspension-type pharmaceutical product with controlled dissolution

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4479954A (en) 1981-05-29 1984-10-30 Eisai Co., Ltd. Piperazine substituted carboxamide derivatives, compositions and method of use
US4978752A (en) 1987-12-04 1990-12-18 Takeda Chemical Industries, Ltd. Crystals of cephem hydrochloride
JPH0517440A (en) 1990-07-06 1993-01-26 Sumitomo Pharmaceut Co Ltd New imide derivative
WO1996033185A1 (en) 1995-04-21 1996-10-24 Hexal Pharmaceuticals, Inc. A process for preparing form 1 ranitidine hydrochloride
WO2001058835A1 (en) 2000-02-11 2001-08-16 Degussa Ag Resolution of dl-racemic mixtures
WO2002053140A2 (en) * 2001-01-02 2002-07-11 Pharmacia & Upjohn Company New drug combinations of norepinehrine reuptake inhibitors and neuroleptic agents

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS517440A (en) * 1974-07-08 1976-01-21 Japan Storage Battery Co Ltd
AU2001246861A1 (en) * 2000-04-10 2001-10-23 Sumitomo Pharmaceuticals Co. Ltd. Sustained release preparations

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4479954A (en) 1981-05-29 1984-10-30 Eisai Co., Ltd. Piperazine substituted carboxamide derivatives, compositions and method of use
US4978752A (en) 1987-12-04 1990-12-18 Takeda Chemical Industries, Ltd. Crystals of cephem hydrochloride
CN1020611C (en) 1987-12-04 1993-05-12 武田药品工业株式会社 Process for preparation of cephem hydrochloride
US5780632A (en) 1990-06-07 1998-07-14 Sumitomo Pharmaceuticals Company, Limited Imide derivatives and their production and use
JPH0517440A (en) 1990-07-06 1993-01-26 Sumitomo Pharmaceut Co Ltd New imide derivative
US5532372A (en) 1990-07-06 1996-07-02 Sumitomo Pharmaceuticals Company, Ltd. Imide derivatives, and their production and use
WO1996033185A1 (en) 1995-04-21 1996-10-24 Hexal Pharmaceuticals, Inc. A process for preparing form 1 ranitidine hydrochloride
US5663381A (en) 1995-04-21 1997-09-02 Hexal Pharmaceuticals, Inc. Process for preparing form 1 ranitidine hydrochloride
WO2001058835A1 (en) 2000-02-11 2001-08-16 Degussa Ag Resolution of dl-racemic mixtures
US6673942B1 (en) 2000-02-11 2004-01-06 Degussa Ag Resolution of DL-racemic mixtures
WO2002053140A2 (en) * 2001-01-02 2002-07-11 Pharmacia & Upjohn Company New drug combinations of norepinehrine reuptake inhibitors and neuroleptic agents

Also Published As

Publication number Publication date
BRPI0413081B1 (en) 2018-03-20
KR101085806B1 (en) 2011-11-22
ES2378990T3 (en) 2012-04-19
JPWO2005009999A1 (en) 2006-09-07
EP1652848B1 (en) 2012-02-01
CN100422178C (en) 2008-10-01
CA2538265A1 (en) 2005-02-03
CA2538265C (en) 2012-10-02
EP1652848A4 (en) 2009-04-15
BRPI0413081B8 (en) 2021-05-25
AU2004259305B2 (en) 2009-06-04
EP1652848A1 (en) 2006-05-03
US7605260B2 (en) 2009-10-20
AU2004259305A1 (en) 2005-02-03
JP4610485B2 (en) 2011-01-12
DK1652848T3 (en) 2012-02-27
US20060194970A1 (en) 2006-08-31
AT543817T (en) 2012-02-15
CN1832946A (en) 2006-09-13
WO2005009999A1 (en) 2005-02-03
KR20060052840A (en) 2006-05-19
BRPI0413081A (en) 2006-10-03

Similar Documents

Publication Publication Date Title
USRE45573E1 (en) Process for producing imide compound
US6559314B2 (en) Method for the production of thiazolidin
US20070088032A1 (en) Processes for the Preparation of Benzoimidazole Derivatives
AU760405B2 (en) Method for producing L-phenylephrine hydrochloride
US20160362391A1 (en) Improved Process for the Preparation of Pomalidomide and its Purification
WO2018193090A2 (en) Process for preparation of eliglustat hemitartrate and intermediates thereof
US6384227B2 (en) Racemisation process for use in the manufacture of levobupivacaine and related piperidinecarboxanilide anaesthetic agents
EP0804417B1 (en) Racemisation process for use in the manufacture of levobupivacaine and related piperidinecarboxanilide anaesthetic agents
US7411089B2 (en) Nateglinide crystals
US20070185354A1 (en) Processes for preparing venlafaxine and venlafaxine hydrochloride of form I
JP2005120024A (en) Method for producing 4'-cyano-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methyl-3'-trifluoromethylpropionanilide
US20190241511A1 (en) Polymorphic forms of belinostat and processes for preparation thereof
US6525195B1 (en) Method for obtaining polymorph a from doxazosine mesylate
US8853395B2 (en) Process for the preparation of lurasidone hydrochloride
US6177564B1 (en) Process for the synthesis of N-benzyl-3-(4-fluorophenyl)-1-4-oxazin-2-one
MXPA06001128A (en) Process for producing imide compound
AU730652B2 (en) Method for drying anhydrous paroxetine hydrochloride
JP5397706B2 (en) Method for producing high purity 1-benzyl-3-aminopyrrolidine
EP4071139A1 (en) Crystalline lofexidine hydrochloride
JP4514017B2 (en) Method for producing epinastine hydrochloride
US20020028944A1 (en) L-tartrate of trans-(-)-4-(4-fluorophenyl)-3-hydroxymethylpiperidine compound and process for preparing the same
US20180186750A1 (en) Processes for the preparation of pesticide compounds
US20230084232A1 (en) Compound and method for preparation of lisdexamfetamine
JP4339074B2 (en) Process for producing optically active 1,2-bis (3,5-dimethylphenyl) -1,2-ethanediamine
JP2021520382A (en) Method for preparing 2,2-dimethylpiperazine

Legal Events

Date Code Title Description
AS Assignment

Owner name: SUMITOMO DAINIPPON PHARMA CO., LTD., JAPAN

Free format text: CHANGE OF NAME;ASSIGNOR:DAINIPPON SUMITOMO PHARMA CO., LTD.;REEL/FRAME:033887/0248

Effective date: 20140619

FEPP Fee payment procedure

Free format text: PAYER NUMBER DE-ASSIGNED (ORIGINAL EVENT CODE: RMPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

FPAY Fee payment

Year of fee payment: 8

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 12TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1553); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

Year of fee payment: 12

AS Assignment

Owner name: SUMITOMO PHARMA CO., LTD., JAPAN

Free format text: CHANGE OF NAME;ASSIGNOR:SUMITOMO DAINIPPON PHARMA CO., LTD.;REEL/FRAME:061972/0730

Effective date: 20220401